Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Osteoporosis International

• Publication date

  2018-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-018-4574-xPMID 29923062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases.

  2017cited by this paper
• Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis‐Hyperphosphatemia Syndrome

  2016cited by this paper
• Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis?

  2016cited by this paper
• Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis

  2016cited by this paper
• FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.

  2016cited by this paper
• GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis

  2015cited by this paper
• Hyperostosis-hyperphosphatemia syndrome (HHS): report of two cases with a recurrent mutation and review of the literature

  2015cited by this paper
• Hyperphosphatemic Familial Tumoral Calcinosis: Genetic Models of Deficient FGF23 Action

  2015cited by this paper
• Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature

  2014cited by this paper
• New insights into the FGF23-Klotho axis.

  2014influential reference
• A mildly painful wrist mass

  2014cited by this paper
• Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.

  2014cited by this paper
• Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanisms

  2014influential reference
• Hyperphosphatemic Familial Tumoral Calcinosis: Odontostomatologic Management and Pathological Features

  2014cited by this paper
• A new missense mutation in FGF23 gene in a male with hyperostosis-hyperphosphatemia syndrome (HHS).

  2014cited by this paper
• Tumoral calcinosis: a dental literature review and case report.

  2012cited by this paper
• Fibroblast growth factor 23: state of the field and future directions.

  2012cited by this paper
• Dramatic diminution of a large calcification treated with topical sodium thiosulfate.

  2012cited by this paper
• Tumoral Calcinosis—A Pathogenetic Overview

  2012cited by this paper
• Dentin matrix protein 1 and phosphate homeostasis are critical for postnatal pulp, dentin and enamel formation

  2012cited by this paper
• Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

  2011influential reference
• Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis

  2011cited by this paper
• FGF23 induces left ventricular hypertrophy.

  2011cited by this paper
• An ocular presentation of familial tumoral calcinosis

  2010cited by this paper
• Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule

  2010cited by this paper
• Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations

  2010influential reference
• Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

  2010cited by this paper
• The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis

  2009cited by this paper
• Familial tumoral calcinosis and hyperostosis–hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3

  2009cited by this paper
• Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome

  2009cited by this paper
• Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.

  2009cited by this paper
• Current understanding of klotho.

  2009cited by this paper
• Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

  2009cited by this paper
• FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?

  2009cited by this paper
• FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.

  2009cited by this paper
• Familial Tumoral Calcinosis Caused by a Novel FGF23 Mutation: Response to Induction of Tubular Renal Acidosis with Acetazolamide and the Non-Calcium Phosphate Binder Sevelamer

  2009influential reference
• GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.

  2009cited by this paper
• A case of familial tumoral calcinosis/hyperostosis–hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features

  2009cited by this paper
• Medical Treatment for Tumoral Calcinosis with Eight Years of Follow-up: A Report of Four Cases

  2009cited by this paper
• A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.

  2009cited by this paper
• Overexpression of Fibroblast Growth Factor 23 Suppresses Osteoblast Differentiation and Matrix Mineralization In Vitro

  2008cited by this paper
• Absence of NOTCH2 and Hey2 mutations in a familial Alagille syndrome case with a novel frameshift mutation in JAG1

  2008cited by this paper
• A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome.

  2008cited by this paper
• Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family.

  2008cited by this paper
• Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis.

  2008cited by this paper
• The genetic basis of inherited anomalies of the teeth. Part 1: clinical and molecular aspects of non-syndromic dental disorders.

  2008cited by this paper
• The genetic basis of inherited anomalies of the teeth. Part 2: syndromes with significant dental involvement.

  2008cited by this paper
• Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on Bone

  2008cited by this paper
• The parathyroid is a target organ for FGF23 in rats.

  2007cited by this paper
• Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis

  2007cited by this paper
• Two novel GALNT3 mutations in familial tumoral calcinosis

  2007cited by this paper
• Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.

  2007influential reference
• Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells.

  2007cited by this paper
• A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

  2007cited by this paper
• A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

  2007cited by this paper
• Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.

  2006cited by this paper
• Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred

  2006cited by this paper
• The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.

  2006influential reference
• Tumoral calcinosis: pearls, polemics, and alternative possibilities.

  2006influential reference
• Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family

  2006cited by this paper
• Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors.

  2005cited by this paper
• An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

  2005cited by this paper
• A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification

  2005influential reference
• Vascular calcification

  2005influential reference
• A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

  2005cited by this paper
• A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.

  2005cited by this paper
• A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.

  2005cited by this paper
• The ß-Glucuronidase Klotho Hydrolyzes and Activates the TRPV5 Channel

  2005cited by this paper
• Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders

  2005cited by this paper
• A case of familial tumoral calcinosis in a neonate and review of the literature

  2004cited by this paper
• Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

  2004cited by this paper
• Keratinocyte growth factor: effects on keratinocytes and mechanisms of action.

  2004cited by this paper
• Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis

  2004cited by this paper
• Familial tumoral calcinosis: association with cerebral and peripheral aneurysm formation

  1999cited by this paper
• Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

  1998cited by this paper
• Hydroxyapatite crystals in tumoral calcinosis: a case report.

  1996cited by this paper
• Ocular tumoral calcinosis. A clinicopathologic study.

  1996cited by this paper
• Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide.

  1995influential reference
• Head and neck manifestations of tumoral calcinosis.

  1994cited by this paper
• Familial Tumoral Calcinosis: A Clinical, Histopathologic, and Ultrastructural Study with an Analysis of its Calcifying Process and Pathogenesis

  1993cited by this paper
• Imaging of tumoral calcinosis: new observations.

  1990influential reference
• Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis

  1989cited by this paper
• Tumoral calcinosis revisited — common and uncommon features

  1988influential reference
• Early costochondral calcification in adolescent hyperthyroidism.

  1985cited by this paper
• The syndrome of hyperostosis and hyperphosphatemia.

  1981influential reference
• Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide.

  1980influential reference
• The effect of thyrocalcitonin therapy and phosphate deprivation on tumoral calcinosis.

  1978cited by this paper
• The effect of thyrocalcitonin therapy and phosphate deprivation on tumoral calcinosis.

  1978cited by this paper
• Two Cases

  1944cited by this paper

• Hypercalcemia Complicated by Rhabdomyolysis and Acute Kidney Injury

  2025cites this paper
• Case Report: An Unusual Mimicker of Osteoarthritis

  2025cites this paper
• Phosphate in Physiological and Pathological Mineralization: Important yet Often Unheeded

  2025cites this paper
• Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series

  2024cites this paper
• Clinical Characteristics, Therapeutic Options, and Outcomes in Hyperphosphatemic Tumoral Calcinosis: A Systematic Review

  2023cites this paper
• Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma

  2023cites this paper
• Phosphate Burden and Organ Dysfunction

  2022cites this paper
• The role of biomineralization in disorders of skeletal development and tooth formation

  2021cites this paper
• Primary hyperphosphatemic tumoral calcinosis: a case report

  2021influential citation
• A case report: renal cystic tumoural calcinosis with ossification and bone marrow formation

  2020cites this paper
• Hyperphosphataemic familial tumoral calcinosis: case report of a rare and challenging disease

  2020cites this paper
• Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.

  2020cites this paper
• Identification of proliferative diabetic retinopathy-associated genes on the protein-protein interaction network by using heat diffusion algorithm.

  2020cites this paper
• The Causes of Hypo- and Hyperphosphatemia in Humans

  2020cites this paper
• Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal

  2020cites this paper
• Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23

  2020cites this paper
• Murine Placental‐Fetal Phosphate Dyshomeostasis Caused by an Xpr1 Deficiency Accelerates Placental Calcification and Restricts Fetal Growth in Late Gestation

  2020cites this paper
• Regulation of fibroblast growth factor 23 (FGF23) in health and disease

  2019cites this paper